Guggenheim Hikes Praxis Precision Medicines Target to $800, H.C. Wainwright Lifts to $1,245
Guggenheim raised price target on Praxis Precision Medicines from $760 to $800, maintaining a Buy rating implying over 140% upside; H.C. Wainwright raised target from $340 to $1,245 for 274% upside. Analysts forecast ulixacaltamide will generate $5–10B peak sales in a $15B essential tremor market and relutrigine $6.8B peak sales.
1. Price Target Revisions
Guggenheim analyst raised Praxis Precision Medicines’ price target from $760 to $800 and maintained a Buy rating, indicating more than 140% upside. Earlier, H.C. Wainwright increased its target from $340 to $1,245, projecting 274% upside and reiterating Buy based on updated clinical data and pipeline progress.
2. Ulixacaltamide Market Potential
Ulixacaltamide, Praxis’s lead program for essential tremor, targets a market opportunity exceeding $15 billion. The therapy is projected to deliver peak annual sales between $5 billion and $10 billion, driven by its novel mechanism addressing neuronal excitation-inhibition imbalance.
3. Relutrigine Upside Opportunity
Relutrigine, a secondary pipeline candidate, is expected to contribute significant long-term value once visible in data readouts. Forecasts assign relutrigine peak sales of $6.8 billion, reflecting its potential to address additional central nervous system disorders beyond essential tremor.